Compare the difference in dose-normalized trough and total daily dose necessary to reach the steady state therapeutic goal after conversion from tacrolimus IR to Astagraf XL® in African American kidney transplant recipients.
The purpose of this study is to compare the difference in medication dosage and total daily dose necessary of Astagraf XL® in order to reach therapy goal, when taken with other medications that are routinely used for kidney transplantation, which may stop the development of a substance that can cause long-term damage to the transplanted kidney. African American kidney transplant patients aged 18 and above who are underwent a kidney transplant are eligible to participate. The duration of the study is 3 months.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
25
Medical University of South Carolina
Charleston, South Carolina, United States
Dose-normalized Trough
Difference in dose-normalized trough at steady state before and after conversion from tacrolimus IR to Astagraf XL®
Time frame: Baseline to 3 months post-conversion
Total Daily Dose
Difference in Total Daily Dose necessary for steady state therapeutic goal
Time frame: Baseline to 3 months post conversion
Weight-Based Dose Requirement
Weight-based dose requirements to reach therapeutic goal pre- and post-conversion
Time frame: Baseline to 3 months post conversion
Number of Days to Reach Therapeutic Trough Goal
Days to reach therapeutic goal after conversion
Time frame: Baseline to 3 months post conversion
Dose Modifications
Number of dose modifications from baseline to 3 months post-conversion.
Time frame: Baseline to 3 months post conversion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
≥360mg twice a day